De­vel­op­ers of a key mR­NA de­liv­ery tech, seek­ing a piece of Mod­er­na's Covid rich­es, sue for patent in­fringe­ment

The law­suit that Mod­er­na has been dread­ing fi­nal­ly got to it.

Ar­bu­tus and Genevant have sued the big biotech for in­fring­ing on their patent on a lipid nanopar­ti­cle plat­form that they say was cru­cial to the de­liv­ery of Mod­er­na’s wide­ly-used Covid-19 vac­cine.

And they want a cut of its multi­bil­lion rich­es.

Among oth­er things, the two com­pa­nies are seek­ing:

An award of dam­ages suf­fi­cient to com­pen­sate Ar­bu­tus and Genevant for Mod­er­na’s in­fringe­ment un­der 35 U.S.C. § 284, in no event less than a rea­son­able roy­al­ty on all in­fring­ing sales or oth­er dis­po­si­tions of Ac­cused Prod­uct.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Recon Strategy

Boston, MA, USA